|
Apr 25
|
Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know
|
|
Apr 24
|
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
|
|
Apr 19
|
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
|
|
Apr 18
|
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
|
|
Apr 17
|
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
|
|
Apr 17
|
Are Medical Stocks Lagging Annexon (ANNX) This Year?
|
|
Apr 17
|
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
|
|
Apr 16
|
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
|
|
Apr 16
|
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
|
|
Apr 16
|
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
|
|
Apr 10
|
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
|
|
Apr 9
|
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
|
|
Apr 9
|
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
|
|
Apr 9
|
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
|
|
Apr 9
|
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
|
|
Apr 8
|
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
|
|
Apr 8
|
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
|
|
Apr 8
|
J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio
|
|
Apr 4
|
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
|
|
Apr 4
|
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
|